Hydatiform mole (also known as molar pregnancy) is a subcategory of diseases under gestational trophoblastic disease (GTD), which originates from the placenta and can metastasize. It is unique because the tumor originates from gestational tissue rather than from maternal tissue. Other forms of gestational trophoblastic disease include gestational choriocarcinoma (which can be extremely malignant and invasive) and placental site trophoblastic tumors. Hydatiform mole (HM) is categorized as a complete and partial mole and are usually considered the noninvasive form of gestational trophoblastic disease. Although hydatiform moles are usually considered benign, they are premalignant and do have the potential to become malignant and invasive.
As described previously, hydatiform moles are divided into complete and partial moles. Complete mole is the more common type and does not contain a fetus, whereas in a partial mole there is a deformed, nonviable fetus present. Complete moles are typically diploid, whereas partial moles are triploid. Complete moles tend to cause higher levels of the human chorionic gonadotropin (hCG), which is one of the main clinical features of this process. In incomplete moles, the karyotype is 46,XX 90% of the time and 46,XY 10% of the time. It arises when an enucleated egg is fertilized either by two sperms or by a haploid sperm that then duplicates and therefore, only paternal DNA is expressed. On the other hand, in partial moles, the karyotype is 90% of the time triploid and either 69,XXX or 69,XXY. This karyotype arises when a normal sperm subsequently fertilizes a haploid ovum duplicates and or when two sperms fertilize a haploid ovum. In partial moles, both maternal and paternal DNA is expressed.
There is a very low frequency of hydatiform moles. In North America and Europe, the frequency has been described as 60 to 120/100,000 pregnancies for hydatiform moles. The frequency has been shown to be higher in other countries of the world. Certain risk factors increase the prevalence of molar pregnancies:
Extremes of maternal age:
Greater than 35 years old carries a five to ten-fold increased risk risk
Early teenage years, usually less than 20 years old
Previous molar pregnancy increases the risk 1% to 2% for future pregnancies
Dietary factors including patients that have diets deficient in carotene (vitamin A precursor) and animal fats
As described previously, hydatiform moles arise from the gestational tissue. In whole hydatidiform moles, there is no fetal tissue presents whereas, in partial hydatiform moles, there is some nonviable fetal tissue apparent. Both are due to over-proliferation of the chorionic villi and resulted swelling. They result in high levels of hCG to be produced. To review, in complete moles an enucleated egg is fertilized either by two sperm or a haploid sperm that then duplicates, resulting in only paternal DNA being expressed. Conversely, in partial hydatiform mole, a haploid ovum either duplicates and fertilized by normal sperm or a haploid ovum is fertilized by two sperm, resulting in both the expression of both maternal and paternal DNA.
Hydatiform moles are caused by a proliferation of the villous trophoblast accompanied by swelling of the chorionic villi. As described previously, the main difference between complete and partial hydatidiform histologically is the lack of embryonic/fetal tissue in complete moles, and the presence of-of embryonic tissue in partial moles. Furthermore, in a complete mole, the chorionic villi are diffusely hydropic and typically are surrounded by hyperplastic trophoblasts. In a partial mole there normal chorionic villi and embryonic/fetal tissue mixed with hydropic villi.
The presentation of the hydatiform mole is somewhat different in a complete mole versus a partial mole. In fact, most partial moles are diagnosed as spontaneous abortions that are later discovered after a pathology report is obtained from the fetal tissue.
Since the advent of ultrasonography, the diagnosis of complete molar pregnancies has increased in the early stages of pregnancy, mainly during the first trimester. The most common symptom (in one study as high as 84% of patients) of a complete mole is vaginal bleeding in the first trimester which is normally due to the molar tissue separating from the decidua, resulting in bleeding. The typical buzz word appearance of the vaginal bleeding is described as a "prune juice" appearance. This is secondary to the accumulated blood products in the uterine cavity and resultant oxidation and liquefaction of that blood. Another symptom of a complete molar pregnancy is hyperemesis (severe nausea and vomiting) which is due to the high level of the hCG hormone circulating in the bloodstream. Some patients also endorse passage of vaginal tissue described as grape-like clusters or vesicles. Late findings of the disease (after the first trimester around 14 to 16 weeks of pregnancy) including signs and symptoms of hyperthyroidism, including tachycardia and tremors, again caused by the high levels of circulating hCG. Other late sequelae are pre-eclampsia which is pregnancy-induced hypertension and proteinuria and/or end-organ dysfunction occurring typically after 34 weeks of pregnancy. When a patient less than 20 weeks pregnant presents with signs and symptoms of pre-eclampsia, a complete molar pregnancy should highly be suspected. In very advanced cases, patients present with severe respiratory distress possible from embolism of the trophoblastic tissue into the lungs.
The presentation of a partial hydatiform mole is usually less dramatic than that of a complete mole. These patients typically present as described before with symptoms similar to a threatened or spontaneous abortion including vaginal bleeding. Since partial hydatiform moles have a fetal tissue, on examination, these patients may have fetal heart tones evident on Doppler.
On physical exam, more than 50% of cases, uterine size discrepancy and date discrepancy usually takes place. In a complete mole, the uterus is usually larger than the expected gestational date of the pregnancy, whereas, in partial moles, the uterus can be smaller than the suggested date.
In a pregnant patient with vaginal bleeding, one should always obtain a serum quantitative hCG level and patient's blood type. In hydatiform moles, the serum hCG levels are typically much higher than patients of the same gestational date in a normal pregnancy or ectopic pregnancy. Complete moles tend to have very high levels of serum hCG, typically greater than 100,000, whereas partial moles may be within normal range for gestational age or even lower than expected. Blood type is important because most patients with complete or partial hydatiform moles present with vaginal bleeding, and therefore Rh antibody screening needs to be performed to determine whether anti-D immunoglobulin needs to be administered if the patient is Rh(D) negative. Other laboratory tests include:
Complete blood count (CBC) (to evaluate for anemia and thrombocytopenia)
BMP (to evaluate for electrolyte imbalance and renal insufficiency)
Thyroid panel (if signs and symptoms of hyperthyroidism present)
Liver function tests and urinalysis (if pre-eclampsia is suspected to evaluate for transaminitis and proteinuria)
Coagulation profile including PT/INR to evaluate for disseminated intravascular coagulation in severe cases.
The imaging of choice in a suspected hydatiform mole is a pelvic ultrasound. In a complete mole, the ultrasound findings include a heterogeneous mass in the uterine cavity with multiple anechoic spaces, most commonly referred to as a "snowstorm" appearance. These small cystic areas are typically the hydropic villi described previously in the histopathology section. Furthermore, there is the absence of an embryo or fetus, and no amniotic fluid is present. In a partial mole, there typically is the finding of a fetus which may be viable, the presence of amniotic fluid, and the placenta appears to have enlarged, cystic spaces (often described as "Swiss cheese" appearance). In one study, it was noted that partial moles were diagnosed as a missed or incomplete abortion in 15% to 60% of cases.
If a molar pregnancy is diagnosed, the next step is typically a chest x-ray to determine metastasis. Furthermore, a chest x-ray should be obtained if patient's initial symptoms include any signs of respiratory distress or increased work of breathing to evaluate for pulmonary edema.
In the emergency department, one must first stabilize the patient. If there is any evidence of respiratory distress and pulmonary edema, one should initiate non-invasive positive pressure ventilation (such as BiPAP) or initiate mechanical ventilation emergently. Furthermore, if there are signs of symptoms of eclampsia (late stage of pre-eclampsia) including seizures, one should initiate appropriate management including benzodiazepines and magnesium sulfate administration. If the patient has signs of pre-eclampsia, urgent blood pressure control is necessary with medications such as hydralazine and labetalol. If there are signs and symptoms of hyperthyroidism, practitioners should initiate proper treatment including beta blockers and monitor for thyroid storm. If severe anemia is present, the clinician should consider a blood transfusion. As discussed earlier, if a patient is Rh(D) negative, the physician should administer the anti-D immunoglobulin.
Once the patient is stabilized, an emergent obstetrics consultation is necessary for the likely need of dilation and curettage (D and C). In patients with advanced maternal age typically greater than 40 years old and those who have completed childbearing, hysterectomy is often performed instead of a D and C. Hysterectomy, however, does not reduce the risk of invasive disease. After the evacuation of the molar pregnancy, if the hCG levels remain elevated, there is evidence of persistent or invasive disease requiring malignancy workup and at times chemotherapy. A gynecology oncology consultation is usually necessary in these cases to guide therapy.
Once molar pregnancy is diagnosed, and an obstetric/gynecology consultation is obtained, patients are typically admitted to the hospital for surgery. Weekly serum hCG levels are obtained after surgery until an undetectable level of hCG is reached (usually done in an outpatient setting). Patients with previous molar pregnancy are advised to use reliable contraception to avoid a new pregnancy, as it could conflict with weekly serum hCG level testing and make it impossible to determine the occurrence of invasive molar disease. The risk of invasive disease in a complete molar pregnancy is around 15% to 20%, and in a partial molar pregnancy is 1% to 5%.
|Molecular and Immunohistochemical Characteristics of Complete Hydatidiform Moles., Kubelka-Sabit KB,Prodanova I,Jasar D,Bozinovski G,Filipovski V,Drakulevski S,Plaseska-Karanfilska D,, Balkan journal of medical genetics : BJMG, 2017 Jun 30 [PubMed PMID: 28924538]|
|Gestational Trophoblastic Disease: Clinical and Imaging Features., Shaaban AM,Rezvani M,Haroun RR,Kennedy AM,Elsayes KM,Olpin JD,Salama ME,Foster BR,Menias CO,, Radiographics : a review publication of the Radiological Society of North America, Inc, 2017 Mar-Apr [PubMed PMID: 28287945]|
|Clinical and radiological correlations in patients with gestational trophoblastic disease., Lima LL,Parente RC,Maestá I,Amim Junior J,de Rezende Filho JF,Montenegro CA,Braga A,, Radiologia brasileira, 2016 Jul-Aug [PubMed PMID: 27777478]|
|Sonographic diagnosis of partial versus complete molar pregnancy: A reappraisal., Savage JL,Maturen KE,Mowers EL,Pasque KB,Wasnik AP,Dalton VK,Bell JD,, Journal of clinical ultrasound : JCU, 2017 Feb [PubMed PMID: 27696434]|
|Complete molar pregnancy in adolescents from North and South America: Clinical presentation and risk of gestational trophoblastic neoplasia., Soares RR,Maestá I,Colón J,Braga A,Salazar A,Charry RC,Sun SY,Goldstein DP,Berkowitz RS,, Gynecologic oncology, 2016 Sep [PubMed PMID: 27423380]|
|Early First-Trimester Appearance of a Hydatidiform Mole on Sonography: The "Snowball" Sign., Chan S,Grant EG,Chen FK,Jayasinha YM,Gulati M,, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2016 Jul [PubMed PMID: 27353689]|